Ufp Technologies (UFPT)
NASDAQ:UFPT
Want to see UFPT full AI Analyst Report?
Top Page
Ufp Technologies
(NASDAQ:UFPT)
Select Model
Select Model
Rating:77Outperform
Price Target:
$262.00
▲(29.46% Upside)
Action:UpgradedDate:05/09/26
The score is driven primarily by strong underlying financial profitability and returns, with a manageable leverage profile despite elevated absolute debt and softer recent growth/FCF trends. Technicals are supportive with the stock trading above major moving averages and positive MACD, but momentum is somewhat stretched. Valuation is reasonable but not clearly cheap at ~21x earnings, and the earnings call reinforced a constructive 2H 2026 ramp outlook while acknowledging near-term execution and demand headwinds.
Positive Factors
Profitability & ROE
UFP exhibits durable sector-leading profitability and strong ROE, which supports reinvestment, capacity build, and acquisitive growth without immediate dilution. Consistent margins imply pricing power and cost control across contract manufacturing cycles, aiding multi‑quarter resilience.
Negative Factors
Slowing Organic Growth
Organic growth has decelerated to near zero as legacy nonmedical demand softens and new programs remain in early ramps. Sustained reliance on program launches to drive growth increases execution risk and could delay durable revenue expansion over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability & ROE
UFP exhibits durable sector-leading profitability and strong ROE, which supports reinvestment, capacity build, and acquisitive growth without immediate dilution. Consistent margins imply pricing power and cost control across contract manufacturing cycles, aiding multi‑quarter resilience.
Read all positive factors
Ufp Technologies (UFPT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.78B
Dividend YieldN/A
Average Volume (3M)185.99K
Price to Earnings (P/E)21.4
Beta (1Y)1.29
Revenue Growth11.19%
EPS Growth7.61%
CountryUS
Employees4,146
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)8.90
Shares Outstanding7,713,300
10 Day Avg. Volume190,467
30 Day Avg. Volume185,990
Financial Highlights & Ratios
PEG Ratio1.63
Price to Book (P/B)4.04
Price to Sales (P/S)2.84
P/FCF Ratio21.66
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue3.11
Enterprise Value/Gross Profit10.98
Enterprise Value/Ebitda16.31
Forecast
1Y Price Target
$289.00Price Target Upside42.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)9.5
Revenue Forecast (FY)$638.97M
Ufp Technologies Business Overview & Revenue Model
Company Description
UFP Technologies, Inc. designs and custom manufactures components, subassemblies, products, and packaging utilizing specialized foams, films, and plastics primarily for the medical market. Its single-use and single-patient devices and components a...
How the Company Makes Money
UFPT makes money by selling custom engineered products and contract manufacturing services, with revenue largely tied to long-term demand from medical device customers. Its core revenue stream is supplying components and subassemblies used in medi...
Ufp Technologies Key Performance Indicators (KPIs)
Ufp Technologies Earnings Call Summary
Earnings Call Date:May 04, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 04, 2026
Earnings Call Sentiment Positive
The call communicated a generally positive operational and strategic trajectory: solid revenue growth (4.1%), strong medical segment performance, margin improvement, meaningful capacity expansions, and successful prior acquisitions. These positives are tempered by short-term headwinds including a 15% decline in nonmedical sales, flat organic growth while new programs ramp, start-up costs dragging near-term EPS, a cyber-related disruption (~$1M of sales shifted and ~$0.5M legal expense), and lingering labor inefficiencies at AJR. Management provided clear mitigation plans (capacity expansion in lower-cost sites, expected ramp in second half, disciplined M&A) and emphasized that many challenges are temporary, supporting an optimistic longer-term outlook.Positive Updates
Top-Line Growth
Revenue increased 4.1% year-over-year (overall sales up ~4%) with medical sales growing 5.9% (reported as 6%), driven by strength in robotic-assisted surgery, patient surfaces & support, and interventional & surgical segments.
Negative Updates
Nonmedical Sales Decline
Nonmedical sales declined 15% year-over-year as the company continues to phase out lower-fit segments (notably automotive) and sees softness in some advanced component markets.
Read all updates
Q1-2026 Updates
Positive
Negative
Top-Line Growth
Revenue increased 4.1% year-over-year (overall sales up ~4%) with medical sales growing 5.9% (reported as 6%), driven by strength in robotic-assisted surgery, patient surfaces & support, and interventional & surgical segments.
Read all positive updates
Company Guidance
Management guided that new‑program revenue should accelerate in the second half of 2026, with four simultaneous launches (three brand‑new, one transfer) expected to be meaningful contributors as three customers have already asked to double capacity; about $1.0M of Q1 sales was pushed into Q2 by a customer cyber event. They expect to pass through raw‑material inflation tied to oil price volatility, noted effective tariffs are net down (a prospective positive for margins) and said supplier refunds could flow to them as vendor credits. Key metrics cited: Q1 revenue +4.1% (medical +5.9%, non‑medical −15%), robotic +7%, patient surfaces & support +11%, interventional & surgical +15%; gross margin 28.8% (vs. 28.5% prior year); adjusted operating margin 16.7%; adjusted EPS $2.48 (up slightly); SG&A up $2.2M to $21M (including ~$750k wages/benefits, ~$0.5M equity comp, ~$0.5M nonrecurring legal); Q1 cash from operations ~$3.2M, capex $1.7M, leverage ~1.14x, and ~$4M debt paid since March 31. They also expect the wound‑care slowdown to be roughly a three‑quarter impact, highlighted a >200% revenue increase in Santiago that helps absorb fixed overhead, plan to take possession of a sixth La Romana building (~+1/6 capacity) and a third Santiago building in Q2, and reiterated M&A will remain a material growth channel (targeting ~50% of growth from acquisitions over multiple years).Ufp Technologies Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
78
Positive
Cash Flow
72
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 608.85M | 602.80M | 504.42M | 400.07M | 353.79M | 206.32M |
| Gross Profit | 172.62M | 170.41M | 146.69M | 112.22M | 90.26M | 51.11M |
| EBITDA | 116.26M | 115.74M | 95.80M | 68.95M | 67.37M | 29.65M |
| Net Income | 68.62M | 68.31M | 58.98M | 44.92M | 41.79M | 15.89M |
Balance Sheet | ||||||
| Total Assets | 674.68M | 665.74M | 629.00M | 404.14M | 378.19M | 334.13M |
| Cash, Cash Equivalents and Short-Term Investments | 19.98M | 20.30M | 13.45M | 5.26M | 4.45M | 11.12M |
| Total Debt | 137.61M | 154.48M | 206.03M | 46.04M | 68.37M | 84.36M |
| Total Liabilities | 235.81M | 241.86M | 286.24M | 118.05M | 140.65M | 139.69M |
| Stockholders Equity | 438.88M | 423.88M | 342.76M | 286.09M | 237.54M | 194.45M |
Cash Flow | ||||||
| Free Cash Flow | 69.44M | 78.98M | 56.94M | 30.84M | 3.96M | 8.90M |
| Operating Cash Flow | 81.30M | 91.91M | 66.59M | 41.33M | 17.74M | 14.29M |
| Investing Cash Flow | -26.47M | -27.60M | -210.16M | -10.49M | 1.29M | -101.46M |
| Financing Cash Flow | -49.08M | -58.16M | 152.39M | -30.02M | -25.89M | 74.05M |
Ufp Technologies Technical Analysis
Neutral
202.38
Price Trends
213.31
Negative
225.20
Negative
220.11
Negative
Market Momentum
-2.87
Negative
51.67
Neutral
51.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UFPT, the sentiment is Neutral. The current price of 202.38 is above the 20-day moving average (MA) of 194.07, below the 50-day MA of 213.31, and below the 200-day MA of 220.11, indicating a neutral trend. The MACD of -2.87 indicates Negative momentum. The RSI at 51.67 is Neutral, neither overbought nor oversold. The STOCH value of 51.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for UFPT.
Ufp Technologies Risk Analysis
Ufp Technologies disclosed 35 risk factors in its most recent earnings report. Ufp Technologies reported the most risks in the "Macro & Political" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Ufp Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $1.78B | 21.36 | 16.61% | ― | 11.19% | 7.61% | |
56 Neutral | $542.87M | -130.15 | -11.00% | ― | 20.19% | 40.88% | |
55 Neutral | $1.11B | 19.55 | 5.40% | 2.02% | 4.78% | -53.80% | |
54 Neutral | $1.08B | -39.25 | -39.90% | ― | 1.24% | -1605.54% | |
54 Neutral | $1.54B | -25.75 | -5.24% | ― | 1.24% | -202.42% | |
53 Neutral | $1.23B | 310.60 | 2.66% | ― | 17.59% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
UFPT
Ufp Technologies
230.55
-13.67
-5.60%
CNMD
Conmed
36.76
-23.52
-39.02%
AORT
Artivion
25.41
-3.36
-11.68%
IART
Integra Lifesciences
13.92
0.25
1.83%
AHCO
AdaptHealth
11.30
2.19
24.04%
SIBN
SI-Bone
12.27
-6.51
-34.66%
Ufp Technologies Corporate Events
Business Operations and StrategyFinancial Disclosures
UFP Technologies Updates Investor Presentation on Medical Growth Strategy
Positive
Feb 27, 2026
UFP Technologies has released updated investor presentation materials outlining its business profile and strategic positioning ahead of meetings with investors and other stakeholders. The March 2026 materials detail the company’s emphasis on...
Business Operations and Strategy
UFP Technologies Expands Key Intuitive Surgical Supply Agreement
Positive
Feb 24, 2026
On February 19, 2026, UFP Technologies, through a wholly owned subsidiary, amended its long-standing Manufacturing Supply Agreement with strategic medical customer Intuitive Surgical, effective January 1, 2026. The amendment extends the contract t...
Business Operations and StrategyExecutive/Board Changes
UFP Technologies Finalizes CEO Succession and Executive Compensation
Positive
Feb 13, 2026
UFP Technologies’ board Compensation Committee met on February 10, 2026 to finalize the previously announced succession plan that will see Mitchell C. Rock become chief executive officer on June 4, 2026, approving his employment terms includ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.